The highest attrition rates during drug development programmes occur at the proof of concept stage. Given the large number of molecules under development for Crohn's disease, a need exists to improve the efficiency of early drug development by fast-tracking promising agents and terminating ineffective ones. Multiple opportunities are available to achieve these goals, including the use of more responsive outcome measures, and the incorporation of sophisticated pharmacokinetic modelling and/or highly specific pharmacodynamic markers into exposure-based dosing regimens and novel trial designs. In this article we review these strategies and propose an integrated paradigm of early drug development in Crohn's disease.
Rationale
The past decade has seen remarkable progress in medical therapy for Crohn's disease [CD] which has been driven by advances in both clinical and basic sciences. New discoveries regarding molecular pathogenesis, candidate pathway identification by genetic association studies and transcriptome analysis, and the ability to perform translational medicine studies in humans have been key drivers of this evolution. From a clinical perspective, emphasis on identifying valid and responsive outcome measures, [1] [2] [3] re-examination of pharmacokinetic [PK]/pharmacodynamic [PD] relationships, [4] [5] [6] and more rigorously designed and larger trials have been notable developments.
The success of tumour necrosis factor [TNF] antagonist therapy has resulted in significant pharmaceutical industry investment in inflammatory bowel disease [IBD] ; over 800 clinical trials targeting IBD are currently planned or under way 7 and a wealth of additional agents are in preclinical development. Whereas this situation has great potential for improved patient care, it also poses a likely challenge to future progress in drug development. 8 This abundance of therapeutic potential places an unprecedented strain on investigator and patient resources that may already be strained. Failure to solve this problem is likely to result in a high rate of programme failure and withdrawal of capital from the field.
Thus, early phase drug development in CD must become more efficient. Although this paradigm and a potential approach to drug development in ulcerative colitis [UC] has been proposed, 9, 1 we feel that the need to address similar concerns for drug development in CD may be more imperative. Consider the conventional model of CD drug development [ Figure 1 ]; a dose-escalation PK/safety study in healthy volunteers is typically followed by a phase 2a combined proof of concept [POC]/parallel and multiple group dose-finding induction trial that employs the use of a clinical outcome measure such as a change in the Crohn's Disease Activity Index [CDAI] score or CDAI-defined remission [typically CDAI < 150] as the primary endpoint. Detection of statistically significant differences using CDAI-based outcomes requires randomisation of approximately 50 patients per treatment group. This model is problematic because the current rate of recruitment for CD trials is an average of 0.1 to 0.2 patients per centre per month and may require up to 125 centres to recruit a three-armed trial [N = 150] within 1 year. 11 Additionally, high placebo rates compromise the ability to detect meaningful therapeutic effects, and may be evidenced in data recently reported for agents in clinical development. 12, 13 Efficient drug development in CD will likely require an integrated strategy that features use of objective outcome measures of inflammation [endoscopy, histopathology, cross-sectional imaging, and biomarkers] [ Table  1 ], patient-based dosing centred on PK/PD evidence, and novel trial design [ Figure 1 ]. In this article we outline the challenges and opportunities inherent in the development of a more efficient paradigm for early drug development in CD.
Components of an Integrated Approach to CD Drug Development

Efficient outcome measures
Conventional outcome measures for CD trials are predominantly symptom-based and empirically derived. The most frequently used efficacy measure in CD clinical trials is the CDAI 14 which is a composite of patient-reported outcomes [PROs; pain, stool frequency, general well-being], physical signs, and a laboratory parameter [haematocrit] . Although use of the CDAI as a primary outcome measure has led to regulatory approval of effective treatments for CD, it has poor specificity to detect active inflammation. 15 Furthermore, it was developed according to accepted methodology 40 years ago and was not created according to rigorous criteria for development of an evaluative index, nor was it developed with any patient input. 16 Regulatory authorities now mandate the use of PROs in CD trials, but no validated CD PROs, as defined by the criteria set forth by the United States Food and Drug Administration [FDA], currently exist. 17 This circumstance is a challenge because an extensive and lengthy process, that is both resource-intensive and costly, is required to develop these instruments. 16 Candidate PROs should be based on items generated from qualitative interviews with patients for whom inflammatory burden is well characterised. These items must be shown to be feasible and interpretable by patients and clinicians. 18 Item reduction, index generation, and formal reliability and responsiveness testing follow sequentially. Initiatives currently under way to create valid PRO instruments will take years to complete.
An empirically derived interim PRO measure, 'PRO2', has been developed to meet regulatory requirements for a symptom-based [non-CDAI] outcome measure.
19 PRO2 is a two-item index comprising the stool frequency [SF] and abdominal pain [AP] items from the CDAI. The total PRO2 score is the sum of the weighted daily SF and AP item scores. Item thresholds are an average daily AP score ≤ 1 point and average daily SF ≤1.5 point. Effect size estimates for treatments of known efficacy [rifaxamin and methotrexate] were similar using either PRO2-or CDAI-defined criteria in the original derivation study, and PRO2 benchmarks corresponding to CDAI scores of 150, 220, and 450 were determined to be 8, 14, and 34, respectively. 19 Other studies, using data from trials of different agents, have shown that SF cutoffs ≥ 3 or alternative thresholds for a weighted 2-item PRO have improved sensitivities and/ or specificities to detect clinical outcomes [typically CDAI-defined remission] [ Table 2 ], suggesting that additional research is needed to define the optimal index. 1, 20 Weighting of the PRO items creates a greater range of scores with potentially superior discrimination that will likely result in the index mapping more closely to the original CDAI. However, weighting of PRO2 may not be acceptable to regulatory authorities, since this is derived by physicians rather than patients. Although symptom-based assessments such as the CDAI are statistically inefficient, PRO2 is likely to serve as an interim outcome measure of symptomatic response in RCTs until a formalised PRO instrument is developed and validated, a process which could take several years. Alternative, more objective measures of inflammation such as endoscopy, magnetic resonance enterography [MRE] , and histopathology should be considered for future early drug development programmes.
Conventional
Endoscopy
As well as demonstrating a beneficial effect on PROs, regulatory authorities also require demonstration of a beneficial effect on an objective measure of inflammation, namely endoscopy, modified total Sharp/van der Heijde score] were required as criteria for treatment success. 21 A similar paradigm has started to emerge in CD clinical trials.
Use of endoscopy at both the enrolment stage and as an outcome measure has the greatest potential to improve trial efficiency in CD. At the enrolment stage, centrally read endoscopy has been shown to minimise site investigator bias and reduce placebo rates in ulcerative colitis trials by ensuring patients have sufficiently active disease and excluding those patients whose symptoms are not due to inflammation. [22] [23] [24] [25] Although empirical data are currently lacking for CD, similar principles are likely to apply. Data from the certolizumab MUSIC study of endoscopic mucosal improvement in CD showed that site investigators consistently overestimated lesion severity compared with central endoscopy readers at all time points, particularly at enrolment. 26 In the SONIC trial, 18% of patients who met the CDAI-based criterion for enrolment [220-450 points] did not have either active disease at ileocolonoscopy or an elevated C-reactive protein [CRP] concentration. 1 A post hoc analysis excluding these patients increased the estimate of treatment effect for combination therapy with infliximab and azathioprine compared with azathioprine monotherapy. These data support the requirement for endoscopically confirmed active disease as an inclusion criterion for induction trials. The theoretical advantages of blinded centrally-read endoscopy as a component of a trial outcome measure are a more precise characterisation of treatment response inherent to consistent scoring by expert readers, and the availability of visual images for auditing by regulatory agencies.
Two Tables 1  and 2 , available as Supplementary data at ECCO_JCC online]. The inherent complexities of the CDEIS, particularly estimation of surface area on a 10-cm scale and estimation of ulcer depth from a two-dimensional image, led to development of the SES-CD. Multiple studies have identified poor correlation of the EIs with the CDAI 29 setting the stage for a debate regarding the relative value of measuring inflammation directly with endoscopy or indirectly, through the secondary consequences of inflammation [pain, stool frequency] that are relevant to patients.
Preliminary validation data for both EIs were obtained during their original development, although systematic evaluation of instrument operating properties has only recently taken place. One study, that employed rigorous methods, demonstrated 'susbstantial' to 'almost perfect' overall inter-rater agreement for both the CDEIS and SES-CD. 30, 29 A consensus process subsequently generated scoring conventions for poor performing index items in an attempt to improve their reliability. Inter-rater reliability for scoring of the SES-CD improved following training on these conventions, but was not improved for scoring of the CDEIS. 31 Based upon these data, we believe that the SES-CD is likely to be the EI of choice for CD clinical trials. Although studies to rigorously assess the relative responsiveness of these EIs are currently under way, multiple questions remain regarding the validity of EIs, including the optimal method to account for unobserved segments and whether removal of stenosis, which is unlikely to be a responsive descriptor, improves index performance.
The use of EIs in clinical trials has historically focused on the binary outcome of remission, although this dichotomisation of data results in loss of information. Use of these instruments as continuous measures has the potential to increase statistical efficiency by using all available data. For example, a recent study that evaluated the responsiveness of the SES-CD and CDEIS suggested per-group sample sizes of 15-27 to detect statistically significant treatment effects [personal communication] . This increased efficiency is attractive for early proof of concept and dose-finding studies. Nevertheless, accurate definition of the responsiveness and minimum clinically important difference for the EI are unmet needs that limit widespread application of this approach. Recently, empirical thresholds have been selected for eligibility [such as a total SES-CD score ≥ 6 for ileo-colonic disease or ≥ 4 for isolated ileal disease] and for outcome assessment [including an SES-CD decrease of 50% or an absolute SES-CD score ≤ 4 for ileo-colonic disease or ≤ 2 for isolated ileal disease]. Studies have used the following SES-CD total score benchmarks to define disease activity, derived by consensus opinion rather than by objective data: remission [0-2]; mild inflammation [3] [4] [5] [6] ; moderate inflammation [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ; and severe inflammation [> 16]. 32 These parameters require confirmation through research using large endoscopic datasets derived from placebo-controlled trials of treatments of known efficacy.
The optimal time point for measuring endoscopic improvement and mucosal healing in CD trials is unknown. In an endoscopic sub-study of the infliximab ACCENT1 trial, colonoscopy was performed at Weeks 0, 10, and 54. 35 The SONIC trial included a secondary endpoint of mucosal healing at Wek 26, which was achieved by 49.3% of patients in the combination arm [azathioprine and infliximab], 30.1% in the infliximab arm, and 16.5% in the azathioprine arm. Although these data suggest that the timing of an optimal endoscopic endpoint may be at least 12 weeks, emerging data may support even later time points, such as 16 or even up to 26 weeks from baseline. This timing, however, may depend on both the outcome definition [endoscopic improvement and/or mucosal healing] and mechanistic factors inherent in the drug. Interim assessment of symptoms at an earlier time point might be warranted to address the extended length of placebo treatment and to allow for patients to either discontinue study treatment or switch to open-label treatment for non-response.
Although a clear imperative exists for the inclusion of both patient-focused and objective measures of disease activity in CD clinical trials, the numerous factors outlined above as well as whether these outcomes should be assessed individually or as composite endpoints continue to be critical research challenges with significant potential to influence the efficiency of early drug development.
Magnetic resonance imaging
MRE has an established role in clinical practice for evaluation of patients with CD. MRE findings are highly predictive of inflammatory activity, can categorise severity, can identify stricturing or penetrating complications, and arguably informs patient management to a greater extent than information obtained from endoscopy. 36, 37 MRE may also be an important outcome component of long-term trials of interventions designed to improve the natural history of CD, characterised by progressive bowel damage in most patients. The Lemann index 38 was recently developed with the aim of measuring cumulative structural bowel damage over time. However, MRE has not been widely adopted as an outcome measure in clinical trials, primarily because the operating properties of the existing MRE indices are incompletely understood.
Several MRE-based quantitative indices of activity have been developed; however, only the Magnetic Resonance Index of Activity [MaRIA] and London indices were derived using endoscopy or surgical resection specimens as a gold-standard comparator. 39, 40 The MaRIA is a composite score that takes into account bowel wall thickness, gadolinium enhancement, ulceration, and oedema, and is highly correlated with endoscopy. 39 Initial validation studies using the MaRIA index have demonstrated reliability and responsiveness to change following treatment with effective therapies. 41, 42 The London index is a composite score that takes into account the semiquantitative measurement of wall thickness and a qualitative assessment of mural signal intensity on T2-weighted sequences, which are used to calculate an acute inflammation score. This index was shown to be correlated with histopathological inflammation in terminal ileal biopsies. 40 A representative MRE image from a patient with CD is shown in Figure 2 . The corresponding MaRIA and London scores are described in the accompanying legend.
Implementation of MRE in clinical trials has specific advantages for both eligibility assessment and as an outcome measure. MRE may be more efficient than ileocolonoscopy for patient selection, because all intestinal segments are visualised, whereas the ileum cannot be examined in up to 25% of patients with active ileitis. 43 In a study assessing the reliability of the MaRia score in 20 patients with CD, MRE was capable of detecting more proximal small bowel inflammation not detected by ileocolonoscopy, as well as penetrating intramural disease and abscesses that would typically be contraindications to trial inclusion. 44 MRE may thus be used to select a more homogeneous, and potentially more responsive, patient population by excluding patients with significant stenosis or penetrating complications. The advantage of MRE to ensure visualisation of all intestinal segments is also relevant when used for outcome assessment. In keeping with US FDA and European Medicine Agency [EMA] guidance regarding the use of imaging tests as outcomes, MRE images can be centrally read off-site by independent adjudicators, and central reading by specialist radiologists minimises reader-related sources of variance. These properties underscore the great potential of MRE as an outcome measure in early CD trials. However, several challenges remain before MRE can be routinely incorporated into CD trials, including: refinement of existing indices, demonstration of responsiveness to change with a treatment of known efficacy, standardization of imaging protocols, and practical and economic considerations.
Histopathology
Histopathology has considerable potential as an outcome measure in CD, but has some notable challenges in comparison with UC. First, unlike UC, CD has a patchy distribution within involved segments, is transmural in nature, and may occur anywhere throughout the gastrointestinal system, including locations that are difficult to biopsy. Second, no evidence-based approach to tissue sampling currently exists. In clinical practice, the usual approach is to avoid biopsying tissue from the centre of ulcers because this location contains necrotic tissue which is uninformative. Accordingly, clinicians usually sample the ulcer edge. However, histopathology is not used to assess disease activity in clinical practice and, as a result, data on the optimal number of biopsy samples and distance from the edge of the ulcer that provides the best information are unknown. Although histological indices for CD do exist, 46 none of these scoring systems has been validated according to modern biometric standards, 47 in distinction to UC where two new histological scoring systems, the Robarts Histopathology Index 48 and the Nancy index, 49 have been developed using appropriate methodologies. Development of a valid CD histopatholgical index according to accepted methodology 50 is a lengthy process 51, 52 which raises the possibility of using either of the existing UC indices on an interim basis until a fully validated CD-specific instrument is available. Finally, whereas histopathological remission is associated with better long-term outcomes such as reduced rates of corticosteroid use, hospitalisation and surgery in preliminary case series for UC, 53 the value of histopathological disease activity as a prognostic factor in CD is unknown and large-scale cohort studies are needed to address this question.
Development of a CD-specific histopathological index or validation of either of the existing UC indices for CD would provide a continuous scoring system for evaluation of inflammatory activity that would complement an EI and increase sensitivity for detection of treatment effects in early-phase studies.
Pharmacokinetics and Pharmacodynamics
Substantial inter-and intra-individual variability in PK has been identified for all biologic treatments for CD. [54] [55] [56] [57] Multiple covariates influence drug PK, including development of anti-drug antibodies [ADA], serum albumin concentration, use of concomitant immunosuppressives, body weight, gender, previous biologic therapy, and the degree of systemic inflammation. Traditional population-based PK modelling, which uses baseline covariates to adjust parameter estimates, is valuable for refining dose regimens; however, physiological conditions change dynamically following treatment. Accounting for the time-dependent nature of covariates has been shown to reduce between-patient variability for parameter estimates in a population PK model for certolizumab pegol, making the model more representative of patient-drug exposure with sustained treatment. 58 Measured or estimated systemic drug exposure in CD has been shown to correlate with response as measured by clinical and endoscopic outcomes or biomarkers. 59, 60 Recently, pre-emptive dose escalation based on infliximab trough concentrations in patients with suboptimal drug exposure has been shown to increase the proportion of CD patients in clinical remission and concomitantly decrease serum C-reactive protein [CRP] concentrations, thereby prospectively confirming the causal relationship between drug exposure and response. 61 Dosing based on exposure is likely to be a valuable tool in early-phase trials of biologics for reducing primary non-response and non-remission rates owing to suboptimal PK. 62 In this regard, we are aware of two drug development programmes that have elected to conduct concurrent conventional fixed-dose and exposure-based dosing strategies in a phase 2 trials. 63, 64 This approach may require a greater number of patients initially, but it is likely to be more efficient should large differences in drug clearance exist at the population level. 65 Although endoscopy is the current gold-standard pharmacodynamic readout for correlation with PK, a meta-analysis on the diagnostic accuracy of serum CRP, faecal calprotectin, and stool lactoferrin showed that all three biomarkers can be sensitive markers of endoscopically-defined disease activity in patients with CD. 66 Nevertheless, some limitations exist to this approach. First, biomarker expression is highly variable at the patient level. For example, a substantial proportion of patients with endoscopically active CD have a normal serum CRP. Second, the distribution of biomarker concentrations is highly skewed, which requires either transformation of data or application of non-parametric testing procedures. Despite these limitations, use of biomarkers of inflammation has shown potential to improve the efficiency of early-phase trials. In a phase 2a study of MEDI2070, a monoclonal antibody that binds to the p19 subunit of IL-23, in patients with active CD, Sands and colleagues compared outcomes using a clinical effect ( 
Immunohistochemistry and Target Engagement
Application of modern translational medicine techniques has great potential to increase the efficiency of early drug development. Direct measurement of target engagement in either peripheral blood, or more relevantly in intestinal tissue, can serve as the basis for a more comprehensive understanding of PK/PD relationships compared with indirect assessment of these relationships using only clinical outcomes. Whereas several examples exist of this paradigm in cancer drug development, 68, 69 there are comparatively few in IBD. For example, to quantitate α 4 β 7 receptor occupancy by vedolizumab in serum, a flow cytometric interference assay was developed to measure MAdCAM-1 Fc binding to α 4 β 7 receptors. 70 In the phase 2 dose-ranging study of vedolizumab in active UC, near complete α 4 β 7 receptor saturation was achieved at all measurable serum concentrations. 71 Yet in later phase 3 trials, an exposure-response relationship was apparent. 72 Biomarkers can also be used for patient stratification. In a phase 2 trial of a β7 integrin antagonist, Vermeire et al. recently demonstrated greater clinical efficacy in patients with high colonic concentrations of the target adhesion molecule. 73, 74 This finding has multiple implications for future drug development programmes and clinical practice, including the possibility of limiting treatment to patients with specific biomarker concentrations or potentially adjusting drug dosing as a function of target tissue concentration. Standardised methods for collection, processing, storage, and analysis of tissue samples must be developed to realise the maximal benefits from this approach.
Special Populations: Fistulising disease
Early drug development for particular subtypes of CD require special consideration. Perianal fistulas, which occur in about one-third of patients, are associated with a disabling disease course. 75, 76 The only proven treatment for these patients is infliximab, which is effective in the short term in approximately two-thirds of patients. Despite a distinct unmet need, few trials of new agents have been initiated for this indication. Although the reasons for this are not obvious, one factor is the limitations of currently available methods to quantify fistula disease activity.
Several clinical activity indices have been developed to evaluate fistulising CD, the most commonly used being the Fistula Drainage Assessment [FDAI] and the Perianal Disease Activity Index [PDAI]. 77, 78 Nevertheless, these indices have not been validated and their operating properties are unknown. Several research initiatives to develop new instruments are sunder way. A new PRO for perianal fistulae has been designed by the St Mark's group in the UK and is currently undergoing validation. MRI holds the greatest promise as a quantitative assessment of fistula disease activity, and MRE is currently considered the gold-standard imaging technique to assess perianal fistulas in clinical practice. The most frequently used MRI-index to measure fistula disease activity is the Van Assche Index [VAI] . However, this empirically designed index has important limitations with respect to item responsiveness 79, 80 and could benefit from modification and further validation studies. The development of validated instruments to assess fistula activity and healing in CD is a clear unmet need.
Trial Design Considerations
Minimisation of placebo response is essential to optimise assay sensitivity during drug development. Randomised controlled trials [RCTs] in CD have shown heterogeneous and sometimes large placebo rates which may have prevented identification of effective therapies. A meta-analysis of placebo rates in CD RCTs conducted 15 years ago, concluded that increasing study visits and duration increased placebo rates, whereas trials enrolling patients with more active disease reduced them. 81 The Apart from enabling sample size calculation for standard frequentist trial design, these contemporary pooled placebo metaanalysis results can be used to inform Bayesian trial designs. A fundamental difference in comparison with classical frequentist design is that Bayesian methods use all relevant and available patient-outcome data during the conduct of trial, and also incorporate historical information. Results are reported as probabilities of treatment effects, can be analysed at any stage during trial conduct, and can help inform decisions about drug development programmes. To our knowledge, only one trial in IBD has been published using this methodology. 82 This approach allowed early termination of a drug development programme for an IL-17 monocloncal antibody after randomisation of only 59 patients: fewer than would have been enrolled by frequentist design.
Phase II clinical trials in CD are typically designed on the basis of detecting a minimally important treatment difference in a primary clinical endpoint. The success of the study is thus dependent on the accuracy of these original assumptions. Adaptive trial designs can incorporate a greater degree of flexibility by enabling planned modifications based upon review of accumulating information during the conduct of a trial. This feature can address some of the uncertainties that are unavoidable in the original design assumptions. 83 In phase II trials, this approach has the potential to increase efficiency by eliminating ineffective treatment arms or altering the randomisation ratio to increase the probability of assigning patients to effective treatment arms. To operationalise this concept practically, outcome data must be incorporated into a central database while patients are being accrued, which must also be linked to the software that determines treatment assignment. 84 This approach holds great potential in phase II IBD trials; the evolution of centralised reading of endoscopy raises the novel possibility of adapting randomisation 'real-time' based upon blinded review of endoscopy as a secondary endpoint, while retaining the primary clinical endpoint. With careful planning and acceptance of these designs by regulators, adaptive designs hold promise as efficient methodologies in CD drug development.
Conclusions and Future Directions
Efficient drug development in CD requires re-evaluation of conventional paradigms. In our view, the greatest opportunity lies in further refinement of endoscopic measures in combination with direct measurement of target engagement in tissue. Such an approach is becoming the standard for early phase trials in UC. Notwithstanding that CD is a more challenging environment, several notable success stories relevant to this paradigm have occurred that should encourage the research community to use novel ways to expedite the process of getting new drugs to market in the most efficient manner.
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